Archives

  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06

    • Angiotensin I (human, mouse, rat) Mechanisms, Clinical Appli

    2025-09-22

    Angiotensin I (human, mouse, rat): Mechanisms, Clinical Applications, and Research Perspectives

    Introduction
    Angiotensin I is a decapeptide precursor in the renin-angiotensin system (RAS), a critical hormonal cascade regulating blood pressure, fluid balance, and electrolyte homeostasis in mammals. Synthesized from angiotensinogen via renin-mediated cleavage, angiotensin I is subsequently converted by angiotensin-converting enzyme (ACE) into angiotensin II, a potent vasoconstrictor and key effector of the RAS (Fyhrquist & Saijonmaa, 2008, J Intern Med). The availability of synthetic Angiotensin I peptides for human, mouse, and rat models—such as those provided by APExBIO—enables precise experimental manipulation of the RAS in both in vitro and in vivo studies. This paper provides a comprehensive review of Angiotensin I’s mechanism of action, clinical value, research applications, and best practices for its use, with a focus on its role in cardiovascular, renal, and metabolic research.

    Clinical Value and Applications
    The RAS is implicated in the pathogenesis of hypertension, heart failure, chronic kidney disease, and several metabolic disorders (Paul et al., 2006, Physiol Rev). Angiotensin I, as a central intermediate, is essential for modeling these conditions in preclinical studies. Synthetic Angiotensin I peptides are widely used to:
    - Investigate the efficacy of ACE inhibitors and angiotensin receptor blockers (ARBs) - Elucidate the molecular mechanisms underlying RAS-mediated pathologies - Develop and validate novel therapeutics targeting the RAS - Study species-specific differences in RAS regulation and pharmacodynamics
    In clinical research, Angiotensin I infusion tests are employed to assess RAS activity, diagnose secondary hypertension (e.g., renovascular hypertension), and evaluate the pharmacodynamic effects of antihypertensive agents (Sealey et al., 1992, Hypertension).

    [Related: ITF2357 (Givinostat)] Key Challenges and Pain Points Addressed
    Despite the centrality of the RAS in cardiovascular and renal disease, several challenges persist in both basic and translational research:
    1. **Species Differences:** Human, mouse, and rat RAS components exhibit sequence and functional differences, complicating the extrapolation of animal data to human physiology (Kobori et al., 2007, Hypertension). 2. **Peptide Stability:** Native Angiotensin I is susceptible to rapid enzymatic degradation in plasma, necessitating careful handling and experimental design. 3. **Assay Specificity:** Accurate quantification of Angiotensin I and its metabolites requires highly sensitive and specific analytical methods, such as mass spectrometry or immunoassays (Danser et al., 2007, Hypertension). 4. **Modeling Pathophysiology:** Traditional models may not recapitulate the complexity of human RAS regulation, highlighting the need for species-specific reagents and genetically modified animals.
    The availability of high-purity, sequence-verified Angiotensin I peptides for multiple species directly addresses these pain points, enabling standardized, reproducible research across laboratories.

    Literature Review
    A growing body of literature underscores the importance of Angiotensin I in both physiological and pathological contexts:
    1. **Fyhrquist & Saijonmaa (2008, J Intern Med):** This review elucidates the RAS cascade, highlighting Angiotensin I as a precursor to bioactive Angiotensin II and its role in vascular tone regulation.
    2. **Paul et al. (2006, Physiol Rev):** The authors detail the molecular biology of the RAS, emphasizing the translational relevance of Angiotensin I in cardiovascular and renal disease models.
    3. **Sealey et al. (1992, Hypertension):** This clinical study demonstrates the diagnostic utility of Angiotensin I infusion tests in differentiating essential from secondary hypertension.
    4. **Kobori et al. (2007, Hypertension):** The paper discusses species-specific differences in RAS components, underscoring the need for tailored reagents in animal research.
    5. **Danser et al. (2007, Hypertension):** The authors review analytical challenges in measuring Angiotensin peptides, advocating for improved assay specificity and sensitivity.
    6. **Crowley et al. (2006, J Clin Invest):** Using mouse models, this study reveals the contribution of Angiotensin I-derived peptides to hypertension and end-organ damage.
    7. **van Kats et al. (2001, Hypertension):** The research quantifies tissue and plasma Angiotensin I levels in rats, providing insights into local versus systemic RAS activity.
    Collectively, these studies establish Angiotensin I as a critical tool for dissecting RAS biology and evaluating therapeutic interventions.

    [Related: AP1903] Experimental Data and Results
    Experimental use of Angiotensin I peptides spans a range of in vitro and in vivo applications:
    - **In vitro assays:** Angiotensin I is used to assess ACE activity in plasma or tissue homogenates. For example, Danser et al. (2007) demonstrated that exogenous Angiotensin I addition enables quantification of ACE inhibition by various compounds.
    - **Animal models:** Crowley et al. (2006) infused Angiotensin I into genetically modified mice, observing dose-dependent increases in blood pressure and cardiac hypertrophy, which were attenuated by ACE inhibitors.
    - **Pharmacodynamic studies:** Sealey et al. (1992) administered Angiotensin I to hypertensive patients, measuring the conversion rate to Angiotensin II as a marker of ACE activity and RAS responsiveness.
    - **Tissue distribution:** van Kats et al. (2001) quantified Angiotensin I in rat tissues, revealing differential local generation and suggesting tissue-specific RAS regulation.
    - **Comparative studies:** Kobori et al. (2007) compared the effects of Angiotensin I in human, mouse, and rat models, highlighting interspecies differences in peptide metabolism and receptor sensitivity.
    These studies consistently demonstrate the utility of synthetic Angiotensin I in probing RAS function, validating pharmacological interventions, and elucidating disease mechanisms.

    Usage Guidelines and Best Practices
    To maximize the reliability and reproducibility of experiments involving Angiotensin I (human, mouse, rat), the following guidelines are recommended:
    1. **Peptide Handling:** Store lyophilized Angiotensin I at -20°C or below. Reconstitute in sterile, buffered saline or water immediately before use. Avoid repeated freeze-thaw cycles to prevent degradation.
    2. **Concentration and Dosing:** Typical in vitro concentrations range from 1 nM to 10 μM, depending on assay sensitivity and cell type. In vivo dosing should be based on published protocols, adjusted for species and experimental objectives (Crowley et al., 2006).
    3. **Controls:** Include vehicle and negative controls to account for non-specific effects. When assessing ACE activity, use known inhibitors (e.g., captopril) as positive controls.
    4. **Analytical Methods:** Quantify Angiotensin I and its metabolites using validated immunoassays or liquid chromatography–mass spectrometry (LC-MS), as recommended by Danser et al. (2007).
    5. **Species Matching:** Use species-specific Angiotensin I peptides to ensure physiological relevance, particularly in comparative or translational studies (Kobori et al., 2007).
    6. **Ethical Considerations:** Adhere to institutional and national guidelines for animal experimentation, including appropriate anesthesia and monitoring during infusion studies.
    7. **Documentation:** Record batch numbers, peptide purity, and sequence information to facilitate reproducibility and data interpretation.
    Following these best practices ensures robust, interpretable results and facilitates cross-study comparisons.

    [Related: sb431542] Future Research Directions
    Several avenues of research promise to expand the utility of Angiotensin I in both basic and translational science:
    1. **Tissue-Specific RAS:** Emerging evidence suggests that local (tissue) RAS systems may function independently of systemic RAS, with distinct roles in organ-specific pathologies (Paul et al., 2006). Further studies using labeled or modified Angiotensin I peptides could elucidate these mechanisms.
    2. **Peptide Modifications:** Development of stabilized or fluorescently labeled Angiotensin I analogs would enable real-time tracking and imaging of RAS dynamics in living systems.
    3. **Genetically Modified Models:** Combining Angiotensin I infusion with transgenic or knockout animals could clarify the contributions of specific RAS components to disease phenotypes (Crowley et al., 2006).
    4. **High-Throughput Screening:** Angiotensin I-based assays are well-suited for screening novel ACE inhibitors, ARBs, or allosteric modulators, accelerating drug discovery pipelines.
    5. **Clinical Translation:** Improved diagnostic protocols leveraging Angiotensin I infusion and advanced analytics may enhance the identification and stratification of patients with RAS-mediated disorders.
    6. **Cross-Species Comparisons:** Systematic studies comparing human, mouse, and rat Angiotensin I responses will refine the translational relevance of animal models and inform the design of preclinical studies. Additional Resources:
    Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 25 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
    https://www.apexbt.com/
    Research Article: PMC11584406